Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTXM6JN)

DTT Name	Cytokine receptor unspecific (CRF)
Gene Name	CRF
DTT Type	Clinical trial target	[1]
UniProt ID	NOUNIPROTAC
TTD ID	T87946

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AD-452	DMMFLXN	Rheumatoid arthritis	FA20	Phase 2	[1]
IRX-2	DMODLN7	Acute myeloid leukaemia	2A60	Phase 2	[2]
------------------------------------------------------------------------------------

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JTE-607	DM1BQFY	Sepsis	1G40-1G41	Discontinued in Phase 2	[3]
VP-025	DM0HZBU	Alzheimer disease	8A20	Discontinued in Phase 1	[4]
VG-106	DMY0V6J	Solid tumour/cancer	2A00-2F9Z	Terminated	[5]
------------------------------------------------------------------------------------

References

1	Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9.
2	Clinical pipeline report, company report or official report of IRX Therapeutics.
3	JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8.
4	List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486.
5	WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same.